UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                              WASHINGTON, DC 20549



                                    Form 8-K
                                     CURRENT


          Pursuant to Section 13 of the Securities Exchange Act of 1934


                Date of Report (Date of earliest event reported):
                                June 30, 2000



                         Meditech Pharmaceuticals, Inc.
              ----------------------------------------------------
             (Exact name of registrant as specified in its charter)



         NEVADA                      000-12561                    95-3819300
---------------------------         -----------              ------------------
(State or other jurisdiction of     (Commission                (IRS employer
incorporation or organization)       File No.)               Identification no.)



             PMB 382, 10105 E. Via Linda, #103, Scottsdale, AZ 85258
     -----------------------------------------------------------------------
              (Address of principal executive offices and zip code)



                                 (480) 614-2874
                               ------------------
                         (Registrant's telephone number)




<PAGE>



Item 5.  Other Events
         ------------

Attached hereto as Exhibit 00.2 is a copy of Meditech Pharmaceutical, Inc.'s
press release dated July 6, 2000 titled "Meditech Pharmaceuticals, Inc. Secures
$30 Million Funding Commitment".

The agreement contains confidentiality provisions designed to safeguard the
confidential information to be shared by the parties under the agreement.


ITEM 7. FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS.
        -------------------------------------------------------------------

     (c) Exhibits

 EXHIBIT
 NUMBER        DESCRIPTION
 ------        -----------
  99.1      Meditech Pharmaceutical, Inc.'s press release dated July 6, 2000
            titled "Meditech Pharmaceuticals, Inc. secures $30 Million Funding
            Commitment:.

<PAGE>



                                   SIGNATURES

Pursuant to the requirements of the Securities and Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.

                                   Signatures
                                   ----------

Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.

                                    Meditech Pharmaceuticals, Inc.
                                    (Registrant)

                                    By: /s/   Gerald N. Kern
                                    -------------------------
                                    Gerald N. Kern
                                    Chief Executive Officer
                                    Date: July 5, 2000
[{"type": "8-K", "sequence": "1", "filename": "0001.txt", "description": "FORM 8-K", "secsgml_size_bytes": 3039}]
{"company-data": {"conformed-name": "MEDITECH PHARMACEUTICALS INC", "cik": "0000717588", "assigned-sic": "2834", "irs-number": "953819300", "state-of-incorporation": "NV", "fiscal-year-end": "0531"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-12561", "film-number": "668951"}, "business-address": {"street1": "10105 E VIA LINDA", "street2": "103 382", "city": "SCOTTSDALE", "state": "AZ", "zip": "85258", "phone": "6026142874"}, "mail-address": {"street1": "10105 E VIA LINDA", "street2": "103 382", "city": "SCOTTSDALE", "state": "AZ", "zip": "85258"}}
UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                              WASHINGTON, DC 20549

                                    Form 8-K
                                     CURRENT

          Pursuant to Section 13 of the Securities Exchange Act of 1934

                Date of Report (Date of earliest event reported):
                                June 30, 2000

                         Meditech Pharmaceuticals, Inc.
              ----------------------------------------------------
             (Exact name of registrant as specified in its charter)

         NEVADA                      000-12561                    95-3819300
---------------------------         -----------              ------------------
(State or other jurisdiction of     (Commission                (IRS employer
incorporation or organization)       File No.)               Identification no.)

             PMB 382, 10105 E. Via Linda, #103, Scottsdale, AZ 85258
     -----------------------------------------------------------------------
              (Address of principal executive offices and zip code)

                                 (480) 614-2874
                               ------------------
                         (Registrant's telephone number)
Item 5.  Other Events
         ------------

Attached hereto as Exhibit 00.2 is a copy of Meditech Pharmaceutical, Inc.'s
press release dated July 6, 2000 titled "Meditech Pharmaceuticals, Inc. Secures
$30 Million Funding Commitment".

The agreement contains confidentiality provisions designed to safeguard the
confidential information to be shared by the parties under the agreement.

ITEM 7. FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS.
        -------------------------------------------------------------------

     (c) Exhibits

 EXHIBIT
 NUMBER        DESCRIPTION
 ------        -----------
  99.1      Meditech Pharmaceutical, Inc.'s press release dated July 6, 2000
            titled "Meditech Pharmaceuticals, Inc. secures $30 Million Funding
            Commitment:.
SIGNATURES

Pursuant to the requirements of the Securities and Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.

                                   Signatures
                                   ----------

Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.

                                    Meditech Pharmaceuticals, Inc.
                                    (Registrant)

                                    By: /s/   Gerald N. Kern
                                    -------------------------
                                    Gerald N. Kern
                                    Chief Executive Officer
                                    Date: July 5, 2000